

o2h Fast Pharma 18

Broaden your CRO base with o2h discovery in India

about o2h Fast pharma 18

o2h discovery has launched Fast Pharma 18, a special and carefully designed all-inclusive FTE package to support pharma and large biotech companies to expedite their synthetic chemistry requirements for their fast-paced medicinal chemistry drug discovery programs.

With o2h Fast Pharma 18, we offer a full-service 18-fume hood lab unit in our new research campus in Ahmedabad, India. Immediate start and no notice period to scale down for six months.



why o2h discovery?

In India, o2h discovery has developed one of the most community-centric, scientifically effective, and environmentally friendly R&D centres in the world. We have ready-to-move-in boutique-style lab spaces that can be allocated for an immediate start.



Scan to read more about o2h discovery's services and offerings

For more information about the o2h Fast Pharma 18, or to get in touch with our experts, visit our website or write us at email address mentioned below:

Highlights

- ✓ Ready to move-in 18 FH capacity secured and dedicated lab space, with card key/biometrics controlled access.
- ✓ 20+ years of drug discovery research experience with large multi-FTE collaborations with large pharma in the UK, USA and Japan.
- ✓ Access to our e-Inventory module with structure search tool, for review of large stock of chemical database @ o2h Discovery stores and @ key reagent suppliers.
- ✓ Full suite of high-end analytical equipment including SFC, several NMR, etc. for thorough and fast compound purification and characterization.
- ✓ Real-time two-tier scientific and project management support with clear communication at the heart of o2h Discovery.
- ✓ Dedicated analytical support for swift troubleshooting, decision making and quality control.
- ✓ Three shift operation mode for round-the-clock reaction monitoring and processing.
- ✓ Highly flexible contract with no notice period to slow down for the first six months.



NeoPhore has worked closely with o2h for over 4 years, consistently supporting NeoPhore with small and medium scale synthesis and characterisation of novel small molecule therapeutics; work that has enabled significant Series A and Series B investment. NeoPhore highly values the synthetic expertise, efficiency, project management and clear communication at o2h. Importantly, o2h benefits from highly integrated analytical and compound purification groups to enable consistent and smooth delivery of high quality target compounds to tight deadlines.

Julian Blagg,

Executive Vice President, Drug Discovery